Komipharm International Co Ltd
Komipharm International Co Ltd is a South Korean pharmaceutical company that develops and commercializes prescription drugs, primarily in the oncology and rare disease therapeutic areas.
Business. Komipharm International Co Ltd (041960.KQ) is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm is headquartered in South Korea and is primarily listed on the KOSDAQ exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Komipharm International Co Ltd (041960.KQ) is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm is headquartered in South Korea and is primarily listed on the KOSDAQ exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.
Komipharm has a market price of 7,600 KRW and a market capitalization of 546.5 billion KRW, with a price-to-book ratio of 7.86 and a price-to-tangible-book ratio of 7.86. The company's enterprise value to EBITDA ratio is 882.11, and its enterprise value to revenue ratio is 10.66. Komipharm's liquidity position is characterized by a current ratio of 1.3 and 27.9 billion KRW in cash and equivalents, but it carries 40.7 billion KRW in long-term debt.
The company's profitability metrics show a return on equity of -10.37% and a return on assets of -5.38%, indicating significant underperformance relative to industry norms. Operating income of 634 million KRW is sharply contrasted by a net loss of 7.2 billion KRW, suggesting operational inefficiencies or high non-operating expenses.
Komipharm's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the latest financial data. The company's revenue of 52.5 billion KRW is derived from its pharmaceutical product portfolio, with no material revenue from services or licensing.
The company's growth trajectory is constrained by negative operating cash flow of 622 million KRW and free cash flow of -9.7 billion KRW, with capital expenditures of -4.5 billion KRW. These figures suggest the company is not generating sufficient cash to fund operations or expansion, and may require external financing to sustain operations.
Komipharm faces medium liquidity risk due to its negative net cash position after subtracting total debt. The company has a low dilution risk, with no near-term pressure for share issuance, and its diluted shares outstanding are equal to basic shares outstanding. The company's debt-to-equity ratio of 0.58 indicates a moderate leverage position.
Recent filings show Komipharm reported a net loss for the period, with operating cash flow and free cash flow both in negative territory. The company's financial statements indicate ongoing challenges in converting revenue to profit and maintaining positive cash flow.
- Komipharm has a high price-to-book ratio of 7.86, suggesting potential overvaluation relative to its equity base.
- The company's return on equity of -10.37% indicates significant underperformance in generating returns for shareholders.
- Komipharm's negative free cash flow of -9.7 billion KRW highlights its inability to generate cash from operations to fund growth or debt obligations.
- The company's liquidity position is medium risk, with a current ratio of 1.3 and negative net cash after debt.
- Komipharm's revenue is concentrated in a single business segment, increasing exposure to market-specific risks.
- "margin_outlook_rationale": "Margins are expected to remain under pressure due to the company's current net loss position and negative operating cash flow.",
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- Komipharm International Co Ltd Market data — financials · 2026-05-26